FDA Eases Animal Tests for Life-Saving Antibody Drugs
Published Date: 12/3/2025
Notice
Summary
The FDA just dropped a draft guide to make safety testing for certain monoclonal antibodies faster and kinder to animals. If you’re a drug developer, this means fewer long tests and less use of primates, saving time and money. Get your comments in by February 2, 2026, to help shape the final rules!
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
Shorter or Skipped Long Toxicology Tests
If you are a drug developer, FDA's draft guidance says general animal toxicology studies for monospecific monoclonal antibodies may not be needed or may be limited to a short-term study. The guidance gives examples when a 3-month or longer animal toxicology study may not be warranted. Submit comments by February 2, 2026 if you want the Agency to consider your input.
Use of Weight-of-Evidence and New Methods
If you develop monoclonal antibodies, the draft guidance allows replacing certain animal safety studies with a weight-of-evidence (WoE) risk assessment. The guidance says a WoE assessment may include new approach methodologies as alternatives to some animal testing.
Changes to Reproductive & Juvenile Testing
The draft guidance provides recommendations on reproductive, developmental, and juvenile toxicity assessments for monospecific monoclonal antibodies. If finalized, those recommendations could change when and what kinds of reproductive or juvenile animal studies sponsors must do.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11739 — Medical Devices; Immunology and Microbiology Devices; Classification of the Simple Point-of-Care Device to Directly Detect SARS-CoV-2 Viral Targets From Clinical Specimens in Near-Patient Settings
The FDA is officially putting simple COVID-19 rapid test devices into a safer, easier-to-manage category called Class II. This change means these tests can get to patients faster and with fewer hoops to jump through, while still making sure they work well and stay safe. Starting June 11, 2026, companies making these tests will follow new rules that help speed up innovation without extra costs.
2026-11740 — Medical Devices; Immunology and Microbiology Devices; Classification of the Spinal Muscular Atrophy Newborn Screening Test System
The FDA is officially putting the Spinal Muscular Atrophy (SMA) newborn screening test into class II, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps make the test safer and easier to get to babies who need it, starting June 11, 2026, with the classification effective since November 2022. Labs and device makers will benefit from clearer rules and faster access, helping catch SMA early without extra costs or delays.
2026-11760 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Establishment, Maintenance, and Availability of Records; Additional Traceability Records for Certain Foods
The FDA is asking for approval to collect extra records from food businesses that handle certain high-risk foods. This helps track food sources quickly to keep everyone safe. Food companies should get ready to keep and share these new records, and comments on this plan are due by July 13, 2026.
2026-11762 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Procedures for the Safe Processing and Importing of Fish and Fishery Products
The FDA is asking for approval to keep collecting info from seafood processors and importers to make sure fish products are safe using a system called HACCP. This affects anyone who processes or imports fish and requires them to keep records showing they’re following safety rules. Comments on this plan are open until July 13, 2026, and there’s no new cost, just a continuation of current paperwork.
2026-11589 — Medical Devices; Ear, Nose, and Throat Devices; Classification of the Combined Acoustic and Electrical External Stimulation Device for the Relief of Tinnitus
The FDA has officially placed the combined acoustic and electrical external stimulation device for tinnitus relief into class II, meaning it now has special safety rules but fewer regulatory hurdles. This change helps patients get access to this innovative device faster and ensures it’s safe and effective. The new classification is effective June 10, 2026, with the rules applying retroactively from March 6, 2023.
2026-11578 — Amending Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use, and Related Information
The FDA just gave a thumbs-up to adding bemotrizinol as a new active ingredient in sunscreens, letting it be used up to 6% concentration. This means sunscreen makers can now include this ingredient, which is safe and effective, in their products. The change is official as of June 10, 2026, and could lead to better sun protection options without extra costs for consumers.
Previous / Next Documents
Previous: 2025-21863 — Agency Information Collection Extension
The Department of Energy is asking to keep collecting feedback from customers and stakeholders for three more years to help improve their services. They want your thoughts on how useful and easy this feedback process is, and you have until February 2, 2026, to share your ideas. This extension won’t cost extra money but aims to make the agency’s work better and smoother for everyone involved.
Next: 2025-21865 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding a closed virtual meeting on January 6, 2026, to review important grant applications about social and environmental health topics. These meetings are private to protect sensitive information and personal privacy. Researchers applying for grants and NIH staff are the main people involved, with no new costs or deadlines announced.